To win the race to biosimilar drug market leadership, Indian pharma firms must complete their digital transformation. Biosimilars are complex, requiring high volumes of structured data, collaboration, and rigorous analysis. Revvity Signals’ tools—like Signals Notebook and Spotfire—enable unified data capture, visualization, and real-time insights across R&D workflows. These tools support advanced analytics, integration, and compliance, helping teams scale faster and reduce risk. Digital transformation is now essential to compete globally in a biosimilars market projected to reach $60B by 2025.

Join for free to read